Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$21.37

1.27 (6.32%)

15:39
08/13/19
08/13
15:39
08/13/19
15:39

Heavy options volume in Aimmune Therapeutics includes protective collar

Heavy options volume in Aimmune Therapeutics includes protective collar. Shares up $1.23, or nearly 6%, to $21.35, with option volumes 15x normal at 5200 contracts, including a buyer of the Sep 17.5/22.5 risk reversal, which a customer traded 2000x vs a $20.75 hedge. Customer bought 2K Sep 17.5 puts and sold 2K Sep 22.5 calls for a 30c debit, opening.

  • 04

    Sep

  • 09

    Sep

  • 13

    Sep

AIMT Aimmune
$21.37

1.27 (6.32%)

07/12/19
ROTH
07/12/19
INITIATION
Target $45
ROTH
Buy
Aimmune resumed with a Buy at Roth Capital
Roth Capital analyst Zegbeh Jallah resumed coverage of Aimmune with a Buy rating and $45 price target, citing his view that AR101 could be a $1B+ opportunity despite debate on the commercial opportunity, especially following the ICER report that was recently published. After having recently sat down with management, he said commercial preparations are continuing at full speed, which Jallah called "a strong indication of management's confidence."
08/05/19
PIPR
08/05/19
NO CHANGE
Target $60
PIPR
Overweight
Aimmune FDA panel could break downward share trend, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Aimmune Therapeutics with a $60 price target after traveling with management. Despite the recent share performance, new money investment in this name, "even in the teeth of the current trend," may make sense, Raymond tells investors in a research note. The analyst thinks the company's September 13 FDA panel meeting for AR101 in peanut allergy "could serve as the catalyst to break the stock's downward trend." Further, Raymond feels "increasingly confident" in a "strong" commercial launch for AR101. Investors "who can look past the scary technicals can be rewarded here," he says.
08/05/19
HCWC
08/05/19
NO CHANGE
Target $25
HCWC
Buy
H.C. Wainwright reiterates Buy on DBV ahead of expected BLA resubmission
H.C. Wainwright analyst Andrew Fein says that as DBV Technologie (DBVT) moves forward towards an anticipated Biologics License Application resubmission for Viaskin Peanut in Q3, he continues to be supportive of the overall value, safety, and efficacy of the Viaskin Peanut program. Following organizational updates, a "straightforward BLA resubmission could refresh investors' confidence in management, while addressing the regulatory overhang," Fein tells investors in a research note. He reiterates a Buy rating on DBV shares with a $25 price target. His confidence in the Viaskin Peanut program has been based on "exceptional safety and sufficient efficacy to manage the risk of accidental exposure." The analyst believes these properties differentiate Viaskin Peanut from the peanut oral immunotherapy being developed by Aimmune (AIMT).
08/09/19
RBCM
08/09/19
NO CHANGE
Target $50
RBCM
Outperform
Aimmune price target lowered to $50 from $58 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Aimmune to $50 after its Q2 earnings miss, also reducing his launch expectations for AR101 based on the analysis of the "recent comparable drug launches into indications with a similar unmet need." The analyst still keeps his Outperform rating on the stock and sees AR101 as well positioned to "disrupt and build the peanut allergy desensitization market".

TODAY'S FREE FLY STORIES

DIS

Disney

$136.70

1.51 (1.12%)

15:37
08/19/19
08/19
15:37
08/19/19
15:37
Periodicals
Former accountant told SEC Disney inflated revenue for years, MarketWatch says »

A former Walt Disney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNET

21Vianet

$7.00

0.17 (2.49%)

15:34
08/19/19
08/19
15:34
08/19/19
15:34
Options
21Vianet options imply 18.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

NGL

NGL Energy Partners

$13.35

0.53 (4.13%)

15:32
08/19/19
08/19
15:32
08/19/19
15:32
Hot Stocks
NGL Energy Partners CEO acquires 60,000 common units »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USPH

U.S. Physical Therapy

$136.10

1.54 (1.14%)

15:30
08/19/19
08/19
15:30
08/19/19
15:30
Hot Stocks
U.S. Physical Therapy director Mark Brookner sells over $404K shares of stock »

U.S. Physical Therapy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

15:25
08/19/19
08/19
15:25
08/19/19
15:25
General news
Treasury Market Summary »

Treasury Market Summary:…

SNE

Sony

$55.68

-0.04 (-0.07%)

15:19
08/19/19
08/19
15:19
08/19/19
15:19
Hot Stocks
Sony to acquire Insomniac Games, terms not disclosed »

Sony Interactive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$56.40

0.77 (1.38%)

15:19
08/19/19
08/19
15:19
08/19/19
15:19
Options
Fabrinet options imply 11.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 21

    Aug

  • 22

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/19/19
08/19
15:17
08/19/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/19/19
08/19
15:16
08/19/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

15:08
08/19/19
08/19
15:08
08/19/19
15:08
Hot Stocks
FDA approves Nabriva's Xenleta to treat community-acquired bacterial pneumonia »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 09

    Sep

IQ

iQIYI

$18.29

1.21 (7.08%)

15:04
08/19/19
08/19
15:04
08/19/19
15:04
Options
iQiyi options imply 16.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

ADI

Analog Devices

$111.23

0.73 (0.66%)

15:00
08/19/19
08/19
15:00
08/19/19
15:00
Recommendations
Analog Devices analyst commentary  »

RBC says focus of Analog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

BIDU

Baidu

$104.30

7.65 (7.92%)

14:49
08/19/19
08/19
14:49
08/19/19
14:49
Options
Baidu options imply 14.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 04

    Sep

AVYA

Avaya

$12.27

-0.25 (-2.00%)

14:46
08/19/19
08/19
14:46
08/19/19
14:46
Periodicals
Avaya said to get bid from Mitel, Bloomberg says »

Avaya is weighing a bid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

TXG

10x Genomics

$0.00

(0.00%)

14:46
08/19/19
08/19
14:46
08/19/19
14:46
Syndicate
10x Genomics files for IPO, to list on Nasdaq under symbol 'TXG' »

10x Genomics filed an S-1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.05

0.085 (0.95%)

14:45
08/19/19
08/19
14:45
08/19/19
14:45
Periodicals
Ford to build two new midsize EV crossovers, Automotive News reports »

Ford Motor plans to build…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

HIIQ

Health Insurance Innovations

$17.42

-0.11 (-0.63%)

14:45
08/19/19
08/19
14:45
08/19/19
14:45
Options
Health Insurance Innovations call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

LAZ

Lazard

$34.27

1.14 (3.44%)

14:43
08/19/19
08/19
14:43
08/19/19
14:43
Periodicals
Lazard seen as top contender for role in Saudi Aramco IPO, Bloomberg says »

Lazard's success on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$41.98

4.93 (13.31%)

14:39
08/19/19
08/19
14:39
08/19/19
14:39
Upgrade
Weibo rating change  »

Weibo upgraded to Buy at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

FB

Facebook

$186.22

2.8 (1.53%)

14:33
08/19/19
08/19
14:33
08/19/19
14:33
Hot Stocks
Facebook says removing 'coordinated inauthentic behavior' from China »

Facebook's Nathaniel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

GOOG

Alphabet

$1,201.56

24.62 (2.09%)

, GOOGL

Alphabet Class A

$1,203.66

24.97 (2.12%)

14:32
08/19/19
08/19
14:32
08/19/19
14:32
Periodicals
'Cyberpunk 2077' coming to Google Stadia, Verge reports »

Google (GOOG) announced…

GOOG

Alphabet

$1,201.56

24.62 (2.09%)

GOOGL

Alphabet Class A

$1,203.66

24.97 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

TRP

TC Pipeline

$48.70

0.3 (0.62%)

, SRE

Sempra Energy

$139.87

0.93 (0.67%)

14:31
08/19/19
08/19
14:31
08/19/19
14:31
Periodicals
Mexico near pact with pipeline builders, Reuters reports »

Mexico is close to…

TRP

TC Pipeline

$48.70

0.3 (0.62%)

SRE

Sempra Energy

$139.87

0.93 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$42.03

4.98 (13.44%)

14:30
08/19/19
08/19
14:30
08/19/19
14:30
Upgrade
Weibo rating change  »

Weibo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

NBRV

Nabriva Therapeutics

$2.13

-0.14 (-6.17%)

14:28
08/19/19
08/19
14:28
08/19/19
14:28
Hot Stocks
Breaking Hot Stocks news story on Nabriva Therapeutics »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 09

    Sep

LAZ

Lazard

$33.90

0.77 (2.32%)

14:24
08/19/19
08/19
14:24
08/19/19
14:24
Periodicals
Breaking Periodicals news story on Lazard »

Lazard seen as top…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.